Chardan Capital analyst Gbola Amusa reiterated a Buy rating on Adverum Biotechnologies (NASDAQ:ADVM) on Wednesday, setting a price target of $20, which is approximately 50.15% above the present share price of $13.32.
Amusa expects Adverum Biotechnologies to post earnings per share (EPS) of -$0.31 for the first quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Moderate Buy rating of shares in Adverum Biotechnologies, with an average price target of $22.8.
The analysts price targets range from a high of $30 to a low of $13.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $0 and a net profit of -$28 million. The company's market cap is $1.25 billion.
According to TipRanks.com, Chardan Capital analyst Gbola Amusa is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 36.4% and a 53.08% success rate.
Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr. and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.